3002.51.00.00/NK Cell Therapy for Solid Tumors/Japan

NK Cell Therapy for Solid Tumors from Japan

Natural killer (NK) cells from peripheral blood, cytokine-activated and expanded for adoptive transfer in treating melanoma and other solid tumors. As modified cell cultures for cancer immunotherapy, they classify under HTS 3002.51.00.00 cell therapy products. These cells directly lyse tumor targets without prior sensitization.

Duty Rate — Japan → United States

0%

Rate breakdown

9903.03.030%Articles the product of any country, as provided for in subdivision (aa)(ii) of U.S. note 2 to this subchapter
Calculate with your customs valueVerify classification with AI

Import Tips

• Provide cytokine activation protocols and flow cytometry data confirming NK phenotype

• Use validated cryopreservation media to ensure >70% post-thaw viability

• Avoid bulk import without patient-matching; declare as personalized medicine